Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATH: Continued Access Study for HIV Treatment
NCT07393659Phase 3Recruiting
- Sponsor
- ViiV Healthcare
- Start
- Jul 2026
- Primary completion
- Sep 2032
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of fostemsavir, dolutegravir, lamivudine in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Started Jul 2026; status: recruiting.
02
Drugs
fostemsavirdolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07393659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07393659.